Chai Discovery says its AI drug design models are used by Eli Lilly, Pfizer, and Novartis
chaitjo · x · 2026-07-29
Chai Discovery says its AI drug design models are now used by Eli Lilly, Pfizer, and Novartis
The post points to an exclusive video about Chai Discovery and its co-founders, Josh Meier and Jack Dent, who left OpenAI and Stripe to build Chai-1/Chai-3, models aimed at designing antibodies in hours rather than years.
Key points from the clip:
- The company claims its models can design antibodies with atomic-level accuracy that has been confirmed in the lab.
- Major pharma companies including Eli Lilly, Pfizer, and Novartis are said to be using the models.
- Chai Discovery has reportedly raised $600M+ from investors including Sequoia, General Catalyst, Thrive Capital, OpenAI, Menlo Ventures, Index Ventures, Kleiner Perkins, and others.
- The video frames the core question as whether AI drug design can materially speed up development for hard diseases.
More from Venture
- Etched Raises $1B Led by Jane Street to Validate Architecture-Agnostic AI Chips — TheTuringPost · 2026-08-24
- Indie dev scales app to $6k/week using hyperrealistic AI UGC — 0x_rxkvys · 2026-08-24
- Fable 5 Makes Up Only 6% of Anthropic Sales — rohanpaul_ai · 2026-08-24
- Whisper kills the moat: Gong's transcription fortress collapses against OpenAI — roxylezan · 2026-08-24
- Virtuals completes first autonomous robot-to-robot transaction on-chain — DonJohnsonSays · 2026-08-24
- Indie dev lessons from Pitch Pit: distribution, clear value, simplicity — DevToD4 · 2026-08-24